Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.62% | -43.56% | -39.77% | -33.32% | -28.48% |
| Total Depreciation and Amortization | -0.66% | 105.38% | 12.52% | 14.83% | 24.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.08% | 12.42% | 49.86% | 101.69% | 91.56% |
| Change in Net Operating Assets | -23.68% | -164.10% | -2,720.75% | 79.62% | -3.20% |
| Cash from Operations | -53.88% | -55.18% | -42.98% | -20.85% | -20.04% |
| Capital Expenditure | 74.02% | 46.67% | 47.21% | 18.59% | 45.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.18% | 249.23% | 285.88% | 224.31% | 258.91% |
| Cash from Investing | 32.12% | 246.46% | 279.94% | 220.63% | 248.13% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 865.48% | -95.15% | -96.22% | -96.24% | -96.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 865.48% | -95.15% | -96.22% | -96.24% | -96.57% |
| Foreign Exchange rate Adjustments | 127.39% | -121.19% | 12.44% | -2,638.00% | -544.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,051.80% | 241.33% | -101.87% | 644.09% | -106.49% |